Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Mantle-Cell 4Lymphoma, B-Cell 4Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Lymphoma, Non-Hodgkin 2Recurrence 1Leukemia, Prolymphocytic 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 160Rituximab 82Peripheral Blood Stem Cell Transplantation 78fludarabine phosphate 75Etoposide 69Filgrastim 67Methotrexate 59Cytarabine 58Vincristine 50Mycophenolic Acid 50Whole-Body Irradiation 48Radiotherapy 43Cyclosporine 43Busulfan 42Tacrolimus 40Melphalan 39Dexamethasone 37Prednisone 36Doxorubicin 36Antilymphocyte Serum 36fludarabine 31blinatumomab 27Methylprednisolone 24Granulocyte Colony-Stimulating Factor 22Carmustine 22Cord Blood Stem Cell Transplantation 21Calcium Dobesilate 18CT-P10 18Inotuzumab Ozogamicin 16sargramostim 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Burkitt Lymphoma × tafasitamab × Clear all
NCT05453500 2026-05-11

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

University of Washington

Phase 2 Active not recruiting
32 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡